Martin Auster
Stock Analyst at Raymond James
(2.77)
# 1,988
Out of 5,072 analysts
56
Total ratings
61.9%
Success rate
14.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $70.99 | +0.01% | 2 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | n/a | $71.20 | - | 2 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $94.11 | +14.76% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $209.03 | +29.65% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $21.67 | +61.51% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $434.23 | -2.36% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $55.50 | +116.22% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $32.78 | +220.32% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $11.74 | +121.47% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $4.91 | +2,343.99% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $725 → $300 | $16.31 | +1,739.36% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $30.34 | +91.17% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $477.20 | -58.93% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $1.51 | +6,390.07% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $206.93 | -71.00% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $41.79 | +55.54% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $18.91 | +286.04% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.11 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $27.78 | +180.78% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.17 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $11.73 | +266.58% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $8.35 | +151.50% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $41.95 | -61.86% | 1 | May 7, 2020 |
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $70.99
Upside: +0.01%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $71.20
Upside: -
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $94.11
Upside: +14.76%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $209.03
Upside: +29.65%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $21.67
Upside: +61.51%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $434.23
Upside: -2.36%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $55.50
Upside: +116.22%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $32.78
Upside: +220.32%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $11.74
Upside: +121.47%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $4.91
Upside: +2,343.99%
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $16.31
Upside: +1,739.36%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $30.34
Upside: +91.17%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $477.20
Upside: -58.93%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.51
Upside: +6,390.07%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $206.93
Upside: -71.00%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $41.79
Upside: +55.54%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $18.91
Upside: +286.04%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $5.11
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $27.78
Upside: +180.78%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $3.17
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $11.73
Upside: +266.58%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $8.35
Upside: +151.50%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $41.95
Upside: -61.86%